SB 203186

Drug Profile

SB 203186

Latest Information Update: 13 Aug 1996

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiemetics
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Nausea and vomiting

Most Recent Events

  • 13 Aug 1996 Discontinued-Preclinical for Arrhythmias in United Kingdom (Unknown route)
  • 13 Aug 1996 Discontinued-Preclinical for Emesis in United Kingdom (Unknown route)
  • 17 May 1995 Preclinical development for Arrhythmias in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top